• Explore /
  • Poster
  • / IMMULAB: A phase II trial of immunotherapy with pembrolizumab in combination with local ablation for patients with early-stage hepatocellular carcinoma (HCC).

IMMULAB: A phase II trial of immunotherapy with pembrolizumab in combination with local ablation for patients with early-stage hepatocellular carcinoma (HCC).

Abstract Poster

Authors

Arndt Vogel

Arndt Vogel

Medizinische Hochschule, Hannover, Germany;

Arndt Vogel , Oliver Waidmann , Tobias Müller , Gabriele Margareta Siegler , Thorsten Oliver Goetze , Enrico N. De Toni , Maria A Gonzalez-Carmona , Guido Hausner , Michael Geissler , Ludwig Fischer von Weikersthal , Angelika M. R. Kestler , Fabian Finkelmeier , Matthias Kleiß , Jens U. Marquardt , Andreas Teufel , Jorge Klagges , Regina Eickhoff , Salah-Eddin Al-Batran , Anna Lena Saborowski

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Gastrointestinal Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract

Track

Pancreatic Cancer,Hepatobiliary Cancer,Neuroendocrine/Carcinoid,Small Bowel Cancer

Sub Track

Therapeutics

Clinical Trial Registration Number

NCT03753659

Citation

J Clin Oncol 41, 2023 (suppl 4; abstr 555)

DOI

10.1200/JCO.2023.41.4_suppl.555

Abstract #

555

Poster Bd #

D7

Abstract Disclosures

Similar Posters

First Author: Arndt Vogel

First Author: A. Dimitrios Dimitrios Colevas

First Author: Arndt Vogel

First Author: Man Jiang